Kite, a Gilead Company (NASDAQ:GILD) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) have entered into a clinical collaboration to conduct a Phase 2, multicenter study of mavrilimumab, in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma.
The objective of the study is to determine the effect of mavrilimumab on the safety of Yescarta. Kite will be the sponsor of this study and will be responsible for its conduct.
Mavrilimumab is an investigational fully-human monoclonal antibody designed to antagonize GM-CSF signaling by binding to the alpha subunit of the GM-CSF receptor.
KNSA shares are up 7% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.